Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07206849 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 5 months later May 2030 → Nov 2030
See other at-risk trials from Nationwide Children's Hospital

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: May 2026 to Nov 2026
    • Primary completion pushed from May 2030 to Nov 2030
    • Study completion pushed from May 2037 to Nov 2037
    v4
  2. Start date: Mar 1, 2026 to May 2026
    • Primary completion date: Mar 1, 2030 to May 2030
    • Study completion date: Mar 1, 2037 to May 2037
    • Collaborators expanded, about 4 words
    v3
  3. Re-verified, no change to tracked fieldsv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this study is to determine the efficacy of the study drugs tovorafenib to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways (MAPK) that this drug targets. The main question the study aims to answer is whether tovorafenib can prolong the life of patients diagnosed with HGG, including DIPG.
Trial Details
NCT Number NCT07206849
Lead Sponsor Nationwide Children's Hospital
Collaborators: Day One Biopharmaceuticals, Inc.
Conditions
(from sponsor)		 High Grade Glioma (HGG) of the Brain With BRAF Aberration, High Grade Glioma (III or IV), Diffuse Intrinsic Pontine Glioma, High Grade Glioma, WHO Grade 3 Glioma, WHO Grade 4 Glioma, Metastatic Brain Tumor
Related terms Brain Neoplasms, Diffuse Intrinsic Pontine Glioma, Glioma
Enrollment 79 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov